Adapt revenue seems to be increasing 20-25% per quarter, Infusions will take a haircut of like 500k next quarter (its down 100k this Q).
Adapt will probs be 3.3m
Infusions 3.6m
So I reckon 6.9m revenue, 12m outflows
5 million out the door.
By my count, on current trends they will have no cash eoq but will have 5 million in line of credit.
They need to either drastically grow Adapt revenues, sell their remaining stake in Vax, sell Infusions, or raise capital to turn this around. Hope they do.
Adapt revenue seems to be increasing 20-25% per quarter,...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.51 |
Change
-0.190(1.21%) |
Mkt cap ! $300.0M | |||
| Open | High | Low | Value | Volume |
| $16.00 | $16.01 | $15.49 | $193.4K | 12.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 82 | $15.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.70 | 75 | 3 |
View Market Depth
| Last trade - 12.50pm 25/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |